Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.William G. Wierda, Hema Sundar, John C. Byrd et al.|PubMed|2020Cited by 143
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapyJennifer L. Crombie, Michael Dickinson, Loretta J. Nastoupil et al.|Blood|2024Cited by 132
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL studyFranck Morschhauser, Loretta J. Nastoupil, Saurabh Dahiya et al.|Nature Medicine|2024Cited by 127
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G. Wierda, Hema Sundar, John C. Byrd et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 94